A simple isocratic HPLC assay to determine linezolid concentrations in different biomatrices for in vivo and in vitro studies

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 8, 2007, Pages 1019-1022

  Swoboda, Stefanie ^a   Ober, Michael ^a   Anagnostakos, Konstantinos ^b   Geiss, Heinrich K ^a   Weigand, Markus A ^a   Hoppe Tichy, Torsten ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Analytics; Pharmacodynamics; Pharmacokinetics; Therapeutic drug monitoring; Tissues

Indexed keywords

ACETONITRILE; ANTIINFECTIVE AGENT; DIALYSIS FLUID; LINEZOLID; WATER;

ACCURACY; ARTICLE; BONE; DIALYSIS; DRUG ANALYSIS; DRUG BLOOD LEVEL; DRUG DETERMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; INFECTION; NONHUMAN; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOFT TISSUE; THAWING; ULTRAVIOLET RADIATION; VALIDATION STUDY;

ACETAMIDES; ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; DRUG STABILITY; HUMANS; OXAZOLIDINONES; REPRODUCIBILITY OF RESULTS;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA;

EID: 34548733698     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.247     Document Type: Article

References (16)

1. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs 2001;61:525-51.
2. Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet 2001;358:1975-82.
3. Mueller M, Brunner M, Hollenstein U, Joukhadar C, Schmid R, Minar E, et al. Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in noninsulin-dependent diabetes mellitus patients. Antimicrob Agents Chemother 1999;43:2056-8.
4. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of "bug and drug". Nat Rev Microbiol 2004;2:289-300.
5. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003;51(Suppl S2):ii17-25.
6. French G. Safety and tolerability of linezolid. J Antimicrob Chemother 2003;51(Suppl S2):ii45-53.
7. Peng GW, Stryd RP, Murata S, Igarashi M, Chiba K, Aoyama H, et al. Determination of linezolid in plasma by reversed-phase high-performance liquid chromatography. J Pharm Biomed Anal 1999;20:65-73.
8. Tobin CM, Sunderland J, White LO, MacGowan AP. A simple, isocratic high-performance liquid chromatography assay for linezolid in human serum. J Antimicrob Chemother 2001;48:605-8.
9. Swoboda S, Fritz S, Martignoni ME, Feldhues R, Hoppe-Tichy T, Buchler MW, et al. Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report. J Antimicrob Chemother 2005;56:787-9.
10. Kielstein JT, Czock D, Schoepke T, Hafer C, Bode-Böger SM, Kuse E, et al. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med 2006;34:51-6.
11. Dager WE. Filtering out important considerations for developing drug-dosing regimens in extended daily dialysis. Crit Care Med 2006;34:240-1.
12. Ehrlich M, Trittler R, Daschner FD, Kummerer K. A new and rapid method for monitoring the new oxazolidinone antibiotic linezolid in serum and urine by high performance liquid chromatography-integrated sample preparation. J Chromatogr B Biomed Sci Appl 2001;755:373-7.
13. Buerger C, Joukhadar C, Muller M, Kloft C. Development of a liquid chromatography method for the determination of linezolid and its application to in vitro and human microdialysis samples. J Chromatogr B Analyt Technol Biomed Life Sci 2003;796:155-64.
14. Borner K, Borner E, Lode H. Determination of linezolid in human serum and urine by high-performance liquid chromatography. Int J Antimicrob Agents 2001;18:253-8.
15. Power BM, Forbes AM, van Heerden PV, Ilett KF. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet 1998;34:25-56.
16. De Paepe P, Belpaire FM, Buylaert WA. Pharmacokinetic and pharmcodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet 2002;41:1135-51.